Ask the pinnacle! An overview of the research and development pipeline of the anti-tumor drug I-Goroche Pharmaceuticals.

Guide: Roche's research and development pipeline focuses on the field of oncology, combined with the future treatment needs of patients, continuous research and development investment, in the existing variety of indications to expand and innovative drug research and development efforts, the strategic characteristics are very prominentrecently, the United States "Pharmaceutical Managers" magazine published the 2020 list of the world's top 50 pharmaceutical companies, the new ranking is a big surpriseThe rise of innovative pharmaceutical companies means that more patients benefit from innovative drugs, and the pharmaceutical company's mission to build a healthy world is realized, Roche topped the list, Pfizer hit WaterlooRoche Pharmaceuticals topped the world with $48.247 billion, and prescription drug sales rose 8.3 percent overall in 2019, breaking Pfizer's four-year dominanceRoche topped the list with a $7.118 billion sale of its 2019 best-selling drug, Avastin, which led Roche's oncology in 2004 when it was approved by the FDA for first-line treatment for colorectal cancerIn addition, Rituxan, the lymphoma treatment drug, and Herceptin, a breast cancer treatment, sold $6.518 billion and $6,078 million, respectivelyPfizer's self-supporting putos patent expired, few bombshells came out, prescription drug labels came from the vaccine field, and the seven-valent pneumococcal polysaccharide-combined vaccine struggled to support the decline in prescription drug salesRoche Pharmaceuticals, the company's best-known Pharma50, marks Roche Pharmaceuticals is not only a "tumor brother", but also a veritable "cosmic pharmaceutical company", the performance behind Roche's decades of research and development investment, and the initial Roche is not starting with cancer drugsii, the tumor of a brother is not necessarily bornRoche early is not a tumor-based pharmaceutical companiesFounded in 1896 and headquartered in Basel, Switzerland,Roche was founded by Fritz Hoffmann-LaRocheAt the beginning of the, Roche pharmaceutical scientists found iodine in thyroid extracts1904, Roche Pharmaceuticals extracted artichoke from ocean yellow to treat a heart attackearly 20th century, Roche Pharmaceuticals began producing psychotropic drugs such as opioid painkillers and anti-epileptic drugs 1933, Roche acquired the synthesis of vitamin C, followed by a series of vitamins, etc., and by the end of the 1970s, Roche's vitamin market share was as high as 50-70% listed in 1963, Valium had sales of $1 billion a year at its peak In the case of anti-tumor drugs, Roche has developed fluorourea, a chemotherapy drug still in use today the mid-1970s, Roche successfully developed The Rocephin, a long-acting antibiotic once a day 1990, Roche controlled Genent for less than $2 billion, and after 2000, Roche became a monoto-resisting company with the help of a growing popularity of querceon, belavzumab and rituximab Roche has been strengthening its research and development properties since its inception and has since reached the top of the world's pharmaceutical industry, especially since 2000, when research and development has spent more than $100 billion , focus, patient needs and innovation, pipeline strategy characteristics 1 Tumor one brother, focusing on winning the future (1) listed products oncology January 30, 2020, Roche announced its 2019 financial results, pharmaceutical business revenue of 48.516 billion Swiss francs, the same year last year increased by 11%, three of the main varieties of Heseltine, Anvitin, Merofa 2019 sales of 19.6 billion Swiss francs, accounting for 40% of its total sales, and the total sales of the tumor business accounted for more than 60% Thus, Roche's revenue depends on the tumor section (2) Research and development pipeline focus tumor Roche in the pipeline layout of the most advantage, a total of 139 pipeline research, rich research and development pipeline, so that Roche will continue to occupy the position of king Roche pipeline is mainly distributed in tumors, immunity, neurological diseases, infectious diseases, ophthalmology and heart metabolism, but the tumor accounted for up to 56%, so that Roche will continue to strengthen the position of the tumor, continue to consolidate the "tumor one brother" throne develop a brother, innovation wins the future of the 48 new drugs approved by the FDA in 2019, 20 are First-in Class, accounting for 42% of the total number of new drugs, these drugs are often different from existing therapies or different mechanisms of action approved 48 new drugs, nine are oncologizing drugs, including Rozlytrek, jointly developed by Genetek and Roche, and Polivy, an antibody drug, which is considered the world's third broad-spectrum cancer-neutral cancer drug Roche has been working to meet the needs of patients, looking to the future, in its research pipeline more bright eye two tumor drugs: (1) Empitini 2017, the FDA approved K drug as "unlimited cancer" (also known as broad-spectrum anti-cancer drugs) therapy, in 2019, and approved the world's third broad-spectrum anti-cancer drug Rochentinib market (2) Antibody Drug Conjugates approved three ADCs in 2019, Roche Pharmaceuticals Polivy, Seattle Genetics/Astellas Padcev, and AstraZeneca/I-Sanpharmaceutical Enhertu To date, the FDA has approved seven ADCs, all of which are used to treat cancer newly listed ADC drugs in recent years are the release, the early listing of Takeda Pharmaceutical synvirus Adcetris and Roche Pharmaceuticals qutodzumab Kadcyla exceeded $1 billion, successfully among the heavy bomb , according to the advisory body, four of the eight ADC drugs will have annual sales of more than $1 billion by 2024, with Roche taking two seats, in addition to The Already Billion-dollar Kadcyla, and 2019-listed Polivy, which has a solid position of 1.393 billion Swiss francs in sales Summary: According to Roche Pharmaceuticals' 2019 Annual Report, Roche's product sales in 2019 were US$63,384 million, with research and development spending of US$12,061 million in 2019 and research and development accounting for 19.03 percent, up 5.87 percent year-on-year (US$11.047 billion in 2018 research and development costs) Research and development costs are among the top ten pharmaceutical companies in the world, and the rate of research and development costs is also among the highest in addition, roche in 2019 in the new indications on the market expansion and innovative research and development, have a good performance: (1) listed products / new indications: "unlimited cancer" personalized drug Empinib (Japan, U.S NTRK gene fusion cancer patients), PDL-1 gene fusion of Atzhu monovirus (U.S., first-line NSCLC), CD20 monoantitheria (China), CD20 Bubble lymphoma, chronic lymphatic leukemia) (2) heavy research and development project: IL-6 antibody Satralizumab listing application accepted
Risdiplam in the treatment of type 2 or 3 spinal muscular dystrophy patients in the key phase 3 trial reached the main end, the U.S FDA has accepted the drug's listing application, and granted priority evaluation qualification
Roche research and development pipeline focused on the field of cancer, combined with future treatment needs, the patient's future research and development In the existing variety of indications to expand and innovative drug research and development efforts, the strategic characteristics are very prominent as competition in the field of oncology becomes more intense and the tumor-related target layout becomes saturated, Roche will continue to lay out pipelines other than tumors, and may also be the future disease spectrum offset defense, or the future treatment of disease hot spots in general, research and development is forward-looking, Roche does and is worth learning data reference source: 2019 Roche Financial Report, China Kang Industrial Capital Research Center .